Categories AlphaGraphs, Earnings, Health Care
Bristol Myers Squibb (BMY) Q4 Earnings: Key financials and quarterly highlights
Bristol Myers Squibb (NYSE: BMY) reported fourth quarter 2021 earnings results today.
Total revenues increased 8% year-over-year to $12 billion, driven by Eliquis, Immuno-Oncology and new product portfolios.
Net earnings attributable to Bristol Myers Squibb was $2.4 billion, or $1.07 per share, compared to a net loss of $10 billion, or $4.45 per share, in the same period a year ago. Adjusted net earnings was $4.1 billion, or $1.83 per share.
For the full year of 2022, worldwide revenues are expected to be approx. $47 billion. GAAP EPS is estimated to be $3.37-3.67 while adjusted EPS is estimated to be $7.65-7.95.
Prior performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
